Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antidiabetic medication
long-acting insulin |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2012 |
| gptkbp:ATCCode |
A10AE06
|
| gptkbp:brand |
gptkb:Tresiba
|
| gptkbp:CASNumber |
844439-96-9
|
| gptkbp:developedBy |
gptkb:Novo_Nordisk
|
| gptkbp:drugClass |
gptkb:insulin
|
| gptkbp:eliminationHalfLife |
25 hours
|
| gptkbp:halfLife |
25 hours
|
| gptkbp:hasMolecularFormula |
C274H411N65O81S6
|
| https://www.w3.org/2000/01/rdf-schema#label |
insulin degludec
|
| gptkbp:indication |
gptkb:diabetes_mellitus
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
insulin receptor agonist
|
| gptkbp:metabolism |
gptkb:kidney
liver |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
<10%
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
gptkb:hypoglycemia
injection site reactions |
| gptkbp:synonym |
IDeg
NN1250 |
| gptkbp:usedFor |
gptkb:type_2_diabetes
type 1 diabetes |
| gptkbp:bfsParent |
gptkb:Ryzodeg
gptkb:Tresiba gptkb:Xultophy |
| gptkbp:bfsLayer |
7
|